Palatin Technologies (PTN) Return on Capital Employed (2011 - 2026)
Palatin Technologies' (PTN) quarterly Return on Capital Employed came in at 49.99% in Q1 2026, down 44029.0% YoY from N/an in Q1 2025, and up 64.43% on a QoQ basis from 140.54% in Q4 2025.
Palatin Technologies (PTN) Return on Capital Employed (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 14 years of Return on Capital Employed data on file, last reported at 49.99% in Q1 2026.
- Quarterly Return on Capital Employed fell 44029.0% year-over-year to 49.99% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 49.99% (down 44029.0% YoY) and the FY2025 annual result came in at 1736.58%, up 221694.0% from the prior year.
- Return on Capital Employed grew to 49.99% in Q1 2026, from 140.54% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 867.85% in Q3 2024 to a low of 3030.18% in Q3 2023.
- A 5-year average of 375.51% and a median of 154.49% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 279183 bps — and 2024, when it jumped 389803 bps.
- Tracing PTN's Return on Capital Employed over 5 years: stood at 191.75% in 2022, then sank by 901 bps to 1918.53% in 2023, then jumped by 126 bps to 490.45% in 2024, then sank by 129 bps to 140.54% in 2025, then soared by 64 bps to 49.99% in 2026.
- The last three Return on Capital Employed figures came in at 49.99% (Q1 2026), 140.54% (Q4 2025), and 221.05% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | -49.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.99% |
| Dec 31, 2025 | -140.54% |
| Sep 30, 2025 | 221.05% |
| Jun 30, 2025 | 386.94% |
| Mar 31, 2025 | 390.30% |
| Dec 31, 2024 | 490.45% |
| Sep 30, 2024 | 867.85% |
| Jun 30, 2024 | -1,588.07% |
| Mar 31, 2024 | -632.57% |
| Dec 31, 2023 | -1,918.53% |
| Sep 30, 2023 | -3,030.18% |
| Jun 30, 2023 | -488.67% |
| Mar 31, 2023 | -205.07% |
| Dec 31, 2022 | -191.75% |
| Sep 30, 2022 | -238.35% |
| Jun 30, 2022 | -154.49% |
| Mar 31, 2022 | -102.09% |
| Dec 31, 2021 | -84.37% |
| Sep 30, 2021 | -68.22% |
| Jun 30, 2021 | -52.51% |